Roche’s Immuno-Oncology Therapy On Course To Indian Debut?
Roche’s cancer immunotherapy Tecentriq has received conditional marketing authorization under India’s layered approval process, setting the stage for a potential debut in the country. However, it remains to be seen how India’s evolving regulations in the area of clinical trial waivers could play out for such products.
You may also be interested in...
Lara Bezerra, Roche’s new managing director in India, outlines in an interview with Scrip how the Swiss multinational is now looking at the Indian market through a different lens and beyond short-term gains.
India’s streamlined clinical trial approvals process appears to have made some gains, but top industry experts tell Pink Sheet how the non-standardized approach of Subject Expert Committees is a “major handicap” for applicants.
Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) appears to be on course to a potential Indian debut, after a key local expert panel recommended the product for marketing.